Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.68 |
| ▸ | CA2 | P00918 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | F2 | P00734 | 2/20 | 0.58 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.49 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9845455 | 0.82 | CA1 (0.70) | CA1CA2ALDH1A1TSHRNPSR1 | |
| SCHEMBL69746 | 0.81 | FFAR1 (0.81) | CA1CA2FFAR1KEAP1LMNA | |
| SCHEMBL4964212 | 0.81 | CA2 (1.00) | CA1CA2ALDH1A1TSHRNPSR1 | |
| SCHEMBL40250 | 0.81 | CA1 (0.68) | CA1CA2ALDH1A1NPSR1FFAR1 | |
| SCHEMBL1429021 | 0.81 | CA1 (0.68) | CA1CA2ALDH1A1NPSR1FFAR1 | |
| Lithium Ion SCHEMBL28445902 | 0.81 | CA1 (0.68) | CA1CA2ALDH1A1NPSR1FFAR1 | |
| SCHEMBL6704542 | 0.80 | CA2 (0.54) | CA1CA2ALDH1A1F2TMPRSS4 | |
| SCHEMBL14744565 | 0.79 | ALDH1A1 (0.66) | CA1CA2ALDH1A1NPSR1FFAR1 | |
| Hydrochloric Acid SCHEMBL25264643 | 0.79 | FFAR1 (0.77) | CA1CA2FFAR1KEAP1LMNA | |
| SCHEMBL25492504 | 0.78 | CA1 (0.64) | CA1CA2ALDH1A1NPSR1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119775367-A | Nectin-4 targeted bicyclic peptide nuclide ligand, probe, and preparation methods and applications thereof | 原子高科股份有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-119775367-A | Nectin-4 targeted bicyclic peptide nuclide ligand, probe, and preparation methods and applications thereof | 原子高科股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-115721729-A | Compounds and methods for treating RNA mediated diseases | 阿拉基斯医疗公司 | 2023-03-03 | — | — | CN | disclosed |
| US-20220402883-A1 | COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION | ARRAKIS THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220402883-A1 | COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION | ARRAKIS THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| CN-108778345-B | Compounds and methods for treating RNA-mediated diseases | 阿拉基斯医疗公司 | 2022-11-29 | — | — | CN | disclosed |
| US-20220281860-A1 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | ARRAKIS THERAPEUTICS, INC. | 2022-09-08 | — | — | US | disclosed |
| US-20220281860-A1 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | ARRAKIS THERAPEUTICS, INC. | 2022-09-08 | — | — | US | disclosed |
| US-20200115372-A1 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | ARRAKIS THERAPEUTICS, INC. | 2020-04-16 | — | — | US | disclosed |
| EP-3478842-A2 | COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION | Arrakis Therapeutics, Inc. (US) | 2019-05-08 | — | — | EP | disclosed |
| CN-109563515-A | Compound and the method for adjusting RNA function | 阿拉基斯医疗公司 | 2019-04-02 | — | — | CN | disclosed |
| EP-3411080-A2 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | Arrakis Therapeutics, Inc. (US) | 2018-12-12 | — | — | EP | disclosed |
| CN-108778345-A | Compounds and methods for treating RNA-mediated diseases | 阿拉基斯医疗公司 | 2018-11-09 | — | — | CN | disclosed |
| WO-2018006074-A2 | COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION | ARRAKIS THERAPEUTICS, INC. (US) | 2018-01-04 | — | — | WO | disclosed |
| WO-2017136450-A2 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | ARRAKIS THERAPEUTICS, INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017136450-A2 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | ARRAKIS THERAPEUTICS, INC. (US) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281860-A1 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | NSUN3, NSUN2, POLRMT | CA1 4668/4885CA2 4711/4885ALDH1A1 2596/4885 |
| US-20200115372-A1 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | NSUN3, NSUN2, POLRMT | CA1 4668/4885CA2 4711/4885ALDH1A1 2596/4885 |
| US-20220402883-A1 | COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION | NSUN3, NSUN2, METTL16 | CA1 4671/4885CA2 4692/4885ALDH1A1 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.